Isolation, characterization, pharmacological evaluation and in silico modeling of bioactive secondary metabolites from *Ziziphus oxyphylla* a member of Rhamnaceae family

Irfan Khan¹, Muhammad Zahoor¹,², Alam Zeb², Muhammad Umar Khayam Sahibzada³*, Wasim U Bari¹, Sumaira Naz²

¹Department of Chemistry, ²Department of Biochemistry, University of Malakand, Chakdara, Dir Lower, KPK 18800, ³Department of Pharmacy, Sarhad University of Science and Information Technology, Peshawar, KPK 25000, Pakistan

*For correspondence: Email: umar.sahibzada@gmail.com

Abstract

**Purpose:** To investigate the pharmacological properties of the medicinally active metabolites of *Ziziphus oxyphylla*.

**Methods:** Compound I-IV were isolated from the root of *Ziziphus oxyphylla* (compound I = Stigmasterol, II = Betulinic acid, III = 1,2,3 benzene triol and IV = 5-Pentadecanoic acid). Various spectroscopic techniques were used to identify and characterize the isolated compounds. DPPH (2,2-diphenyl-1-picrylhydrazyl) and ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) assays were employed to determine the antioxidant potentials of these compounds. The acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibition potential of the isolated compounds were also evaluated.

**Results:** Amongst the isolated compounds, compound IV was the most potent antioxidant against DPPH and ABTS free radicals, exhibiting half-maximal concentration (IC₅₀) values of 64 and 65 µg/mL, respectively. All the compounds exhibited good inhibition of acetylcholinesterase and butyrylcholinesterase. However, stigmasterol was more potent than the other isolated compounds, showing IC₅₀ of 85.10 ± 1.45 and 84.81 ± 1.17, respectively, against AChE and BChE.

**Conclusion:** Although, all isolated compounds inhibited the selected free radicals (DPPH and ABTS) and cholinesterases, stigmasterol and 5-pentadecanoic acid were more potent than other two compounds. Thus the former can potentially be used to treat oxidative stress and neurodegenerative diseases.

**Keywords:** *Ziziphus oxyphylla*, Stigmasterol, 5-Pentadecanoic acid, Antioxidant, Acetyl Cholinesterase, Butyryl cholinesterase

INTRODUCTION

Medicinal plants are valuable sources of bioactive compounds and are used in crude form as traditional medicines. Being factories of natural compounds they provide active ingredients of modern drugs as well [1]. Due to their versatile applications and low incidences of side effects, plant derived substances are preferred by local communities around the world.
and are used as drug for the treatment of many diseases [2]. Plants being the renewable sources, provides low cost drugs and other biologically important substances [3]. Approximately, 80 % inhabitants of the developing countries are using medicinal plants as remedies of different ailments.

A number of bioactive phytochemicals were isolated from plants during the first half of the nineteenth century [4-6]. Many of them are now used as active ingredients in modern drug formulations. A number of herbal drugs have been effectively used for the treatment coronary heart diseases and cancer [7]. Oxidative stress that is caused by the increased production of free radicals in human bodies due to environmental changes and modern food habits, can be controlled by the intake of certain phytochemicals, collectively known as antioxidants. Although, a number of synthetic antioxidants are used as preservatives in the food industry but genotoxic and carcinogenic effects have been reported about them in experimental animals. On the other hand, natural antioxidants that can be obtained from plant, are thus considered safe for systemic uses and are preferred over synthetic antioxidants [3,7].

Alzheimer disease (AD) which can be characterized by common behavioral symptoms like cognitive dysfunction, turbulence, and limitation in the usual activities, is a neurodegenerative disease of the old age [8]. The common indicator of AD is the reduction in the amount of acetylcholine (ACh) as a result of its excessive hydrolysis by AChE and BChE. ACh, being a neurotransmitter, affect the conduction of neuro impulses across the synapses. In such situations, the inhibition of AChE and BChE are desired to minimize the complications associated with AD. Currently, there are five such inhibitors available in the market for the treatment of AD. Amongst them galantamine and rivastigmine are natural products of plant origin [9,10]. None of these five drugs are 100% potent, therefore, improved inhibitors from plants are being sought to develop a new efficient drug for the treatment of AD.

_Ziziphus oxyphylla_ which belongs to the family Rhamnaceae is a very important medicinal plant and is under scientific investigations for the last two decades due their medicinal uses in the folklore medicines [11,12]. Various species of _Ziziphus_ genus are used for the treatment of weakness, gastrointestinal tract, and liver complications. It has also been used to reduce obesity and to treat urinary tract and skin infections, diabetes, fever, diarrhea, insomnia etc. Antibacterial, antifungal, and phytotoxic activities of some species of this genus have already been reported [13].

A number of compounds have also been isolated from this genus. Amongst them nummularine, zizynnummin, lotusanine, adouctine, mauritine, dachuine, franganine and frangufoline are the important compound that have exhibited medicinal properties in animal models [13,14]. Devi and her team isolated nummularine-K, nummularine-R, and amphibinesorbitol H from _Z. nummularia_ while frangufoline from _Ziziphus jujuba_ [15]. Singh and his team isolated nummularine-T from _Ziziphus nummularia_ [16]. Ghedira et al isolated lutsine from _Ziziphus lotus_ [17]. Jubanine-C, an alkaloid was isolated by M. Tripathi and his team from _Ziziphus jujuba_ [18]. The alkaloid lotusine G was isolated from by Crouéour from _Ziziphus lotus_ [19].

To the best of our knowledge, the root of _Ziziphus oxyphylla_ has not been subjected to isolation of biologically active compounds. The medicinal importance of this plant promoted us to isolate biologically active compounds from this plant. Four compounds were isolated in pure form, which were screened for their antioxidant and anticholinesterase potentials.

**EXPERIMENTAL**

In column isolation, the adsorbent silica (particle size = 70 – 230 mesh size, acquired from Merck, Germany) was used. To visualize the isolated compounds, TLC plates (60 PF254, Merck), cesium sulphate, iodine, and UV lamp (local made) were used. Different spectroscopic techniques (\(^{1}H/\(^{13}C\) NMR, COSY, NOESY, etc.) were employed for the structural elucidation of isolated compounds.

**Plant material**

_Ziziphus oxyphylla_, root samples were collected from Barimkai village of Dir District, KPK, Pakistan. The plant was authenticated by a botanist, Dr. Mohammad Nisar (voucher specimen no. 1022HU) and stored in the Herbarium of the University of Malakand, were followed (UOM/HU/Eth/Coll.0321).

The root samples were cleaned with water, shade dried and then ground to a fine powder using grinder. The fine powder was then soaked in 95 % methanol/water solvent system for 75 h. The mixture was then filtered and the leftover solid residues were dipped again in then mentioned solvent system for additional 75 h. The filtrate obtained of both the steps were
mixed together and converted into a semisolid mass at 40 °C using a rotary evaporator (Switzerland, Modal R-200 Buchi, Rotavapor). The crude methanolic extract was then subjected to fractionation using different solvents. About 700 g of the methanolic extract was dissolved in 2000 mL distilled water and then subjected to solvent-solvent extraction. The different fractions obtained were concentrated under vacuum in a rotary evaporator. The semisolid masses obtained were air dried and were kept in refrigerator till further use.

HPLC analysis were used to determine the distribution of phytochemicals amongst the different extract fractions (HPLC system used: Agilent 1260). The ethyl acetate extract had a large number of phytochemicals (based on HPLC findings) and was thus loaded to silica gel column for the isolation. The column was eluted with n-hexane/ethyl acetate solvent system. The eluted fractions were analyzed on TLC plates and identical fractions were combined to get 25 fractions. After passage through pencil silica columns, fraction 13 was found to contain stigmasterol (57 mg) that was eluted with EtOAc/n-hexane (3:7) mixture. Fraction 7 contains two compounds: 1,2,3 benzene triol and 5-pentadecanoic acid (EtOAc/n-hexane, 6: 8). Betulinic acid was purified from fraction 11 and eluted with EtOAc/n-hexane mixture in ratio of 5:5.

Antioxidant screening

DPPH is a synthetic free-radical that is used to assess the antioxidant potential of various samples including plant extracts [9]. About 20 mg/100 mL DPPH solution was prepared in distilled methanol. About 3 mL from this solution was taken and diluted with distilled methanol to adjust its absorbance to 0.700 at 515 nm. The stock solution was then accordingly diluted and was kept in dark for overnight (the time needed to generate DPPH free radical). To prepare the isolated compound stock solutions, 5 mg of each was dissolved in 5 mL methanol. Different dilutions of each compound (1000, 500, 250, 125, and 62.5 μg/mL) were prepared and used in the subsequent experiments as working standards. Then 2 mL DPPH solution was mixed with 2 mL working standards in a number of test tubes and incubated in dark for 15 min. Then the absorbance of each sample was recorded at 515 nm using UV/visible spectrophotometer. The samples antioxidant potential was calculated using equation 1.

\[ R(\%) = \frac{(A-B)}{A} \times 100 \]  

Where “A” denotes the absorbance of oxidized form of DPPH, while “B” is the absorbance of DPPH after mixing with test samples.

ABTS is also a synthetic free radical employed for the in vitro estimation of antioxidant potential of different substances. The free radical stock solution was prepared by a method described by Ovais and his team [9]. About 2 mL ABTS were mixed with 2 mL of the working standards and incubated for a specified interval of time (25 min). The absorbance of resulting mixture after incubation was determined using UV/visible spectrophotometer. Equation 1 was used to calculate the antioxidant potential of tested samples.

Evaluation of anticholinesterase inhibition potential

Ellman’s assay was utilized to estimate anticholinesterase potentials of a given substance. The hydrolysis of acetylthiocholine iodide results in the formation of thiocholine which make a color complex with an anion formed from DTNB (5-thio-2-nitrobenzoate) [20]. From different dilutions of each compound, 1 mL was incubated for 15 min at 25°C with 100 μL of DNTB and AChE/BChE. After incubation, the substrate; acetylcholine/butyrylcholine iodide (100 μL) were added to reaction mixtures and incubated for additional 15 min. The absorbance of reaction mixtures were recorded at 412 nm using spectrophotometer. Equations 2-4 were used to calculate enzyme inhibition.

Rate of reaction = ΔA/ΔT ........................ (2)

\[ Ea(\%) = \frac{(Rate \ of \ reaction)/(Maximum \ rate \ of \ reaction)}{100} \]  

\[ Ei = 100 - %Ea \]  

where \( Ea = \) Enzyme activity, \( Ei = \) Enzyme inhibition, \( A = \) Absorbance, \( V = \) rate of reaction in the presence of inhibitor, \( V_{\text{max}} = \) rate of reaction in the absence of inhibitor.

Phosphate buffer (8.0 pH and 0.1 M) was used to prepare different solution. The pH of solutions were adjusted with potassium hydroxide. The concentrations of enzyme used were; 0.01 and 0.03 Unit/mL of AChE and BChE respectively. Different solutions used in the experiments were prepared in distilled water (0.0005 M acetyl/butyrylthiocholine iodide, 0.0002273 M DTNB). All the solutions were stored at 4°C in a refrigerator till further use. As a positive control, galantamine have been used.
Molecular docking simulations

To establish a correlation between the experimentally observed percent inhibition of AChE/BChE and the possible binding orientations of the compounds with the enzymes crystal structures (PDB: 1ACL, 4BOP: from the RCSB Protein Data Bank), simulation software (Schrödinger) was used. All the ligands studied were in neutral form and optimized in the force field of OPLS-3. To prepare the selected enzyme crystal structures suitable for protonation at pH 7, protein preparation (Schrödinger) was used. The receptor grid box (a 20 Å box containing active site water molecule in its center) was defined. The docking was performed with Glide (Schrödinger) using XP extra precision with evasion settings and glide scoring function, reporting the 15 top ranked poses for each ligand. Visual review of the binding pose and generation of figure was done with (Schrödinger) Maestro [21].

RESULTS

The spectral data of the isolated compounds are presented as follows:

**Compound I (Stigmasterol)**

**Proton NMR:** In $^1$HNMR (DMSO, δ ppm), the multiplet observed at δH 5.35 is due to Exocyclic Methylene Protons (H-6). The detail of remaining peaks is as follow: at δH 5.60 (m, 2H, H-22,23), 4.86 (s, 1-OH, H-3), 3.47 (m), 0.88 (3H, d, J = 6.52 Hz), 0.92 (3-H, d, J = 6.82 Hz), 0.78 (3-H, s, CH3-18), 0.88 (3-H, t, J = 6 Hz), 1.02 δH (3-H, s), 0.83 (3-H, d, J = 6 Hz). Methylene protons were observed between δH 1.20- 2.65.

**Carbon-13 NMR:** The detail of peaks observed in $^{13}$CNMR (DMSO, δ ppm) spectrum are as follow: 33.23 (C-1), 33.04 (C-2), 72.46(C-3), 51.75(C-4), 139.80 (C-5), 122.45 (C-6), 30.40 (C-16,7), 35.12 (C-8), 57.39 (C-9), 49.29 (C-10), 19.33 (C-11), 49.43 (C-12), 51.78 (C-13), (C14,17), 12.67 (C-18), 12.34 (C-19), 49.15 (C-20), 19.48 (C-21), 33.23 (C-26,22), 41.92 (C-23), 52.81 (C-24), 47.30 (C-25), 33.28 (C-27), 37.44 (C-28), 12.53 (C-29).

Figure 1 represents the chemical structure of compound I, which have also been confirmed through HMBC, HSQC and COSY.

**Compound II (Betulinic acid)**

The melting point of compound II was approximately 316 to 318°C. The IR spectra showed characteristic peaks at 3408, 1628, 1379 and 1065 cm$^{-1}$ presenting unsaturation and OH groups. Its molecular formulae is C$_{30}$H$_{48}$O$_{3}$. The observed spectral data was in accordance with the reported IR data of the same compound [20].

$^1$H-NMR (DMSO, δ ppm): The details of proton spectrum (DMSO, δ ppm) is given as follow: the δH at 0.77 (s, 3-H, H-28), 0.88 (s, 3-H, H-29), 0.97 (s, 6-H, H-25 & 26), 1.02 (s, 3-H, H-30), 0.93 (s, 1-H, H-4), 1.06 (s, 1-H, H-12), 1.42 (m, 8-H, H-6, 8.15 & 20), 1.58 (m, 4-H, H-7 & 14), 1.35 (m, 2-H, H-19), 1.71 (s, 3-H, H-24), 1.94 (m, 2H, H-16), 1.56 (m, 4-H, H1 & 13), 2.33 (m, 1H, H-21), 2.25 (m, 1H, H-18), 3.03 (m, 1H, H-2), 4.61 (s, 1-OH, H-27), 3.15 (dd, 1-H, H-23), and 3.03 (t, 1-H, H-23), representing different location and environment of proton present.

$^{13}$C-NMR (DMSO, δ ppm): The detail $^{13}$CNMR (DMSO, δ ppm) is as follow: 15.12 (C-30), 16.10 (C-28), 16.67 (C-7), 16.73 (C-29), 19.46 (C-14), 19.57 (C-24), 22.11 (C-25,26) 26.93 (C-13), 28.07 (C-1), 28.62 (C-15), 30.86 (C-20), 31.75 (C-16), 33.39 (C-8), 35.63 (C-19),38.16 (C-6), 39.70 (C-9), 39.96 (C-11), 48.58 (C-21), 49.29 (C-18), 50.51 (C-10), 56.91 (C-4), 57.53 (C-17), 79.70 (C-2), 110.3 (C-23), 152.03 (C-22), and 180.20 (C-31). The structure of compound II (Betulinic acid) is presented in Figure 2. For final confirmations; HMBC, HSQC, and COSY techniques have been used.

Figure 1: Compound I (Stigmasterol)

Figure 2: Compound II (Betulinic acid)
**Compound III (1, 2, 3 benzene triol)**

It is a white colored amorphous solid, soluble in water having melting point of 131-134°C. The FTIR spectrum showed peaks at 3608, 1628, and 1165 cm⁻¹ indicating the presence of OH and aromatic groups.

**¹H-NMR (DMSO, ppm):** Different peaks observed at δₙ 6.4 (t, J=12 Hz, H-5), 6.2 (d, J = 6 Hz, 2H, H-4 & 6), 8.6 (s, 3-OH, OH-1, 2 & 3) confirmed the compound as 1,2,3-benzene triol.

**¹³C-NMR (DMSO, ppm):** Different positions and environment of carbons were confirmed from peaks at δₙ 146 (C-1 & 3), 133 (C-2), 118.5 (C-5), 107.12 (C-4 & 6). The structure of compound III (Figure 3) was further confirmed through HMBC, HSQC and COSY techniques.

![Figure 3: Compound III (1, 2, 3 benzene triol)](image)

**Compound IV (5-pentadecanoic acid)**

Compound IV is a saturated fatty acid having chemical formulae; C₁₅H₂₆O₂. The melting point recorded for this compound was 51 to 53°C. The data obtained for Compound IV were in agreement with that of pentadecanoic acid already reported in literature. Pentadecanoic acid have been isolated for the first time from the Z. oxyphylla.

**¹H-NMR (DMSO, δppm):** 0.99 (7, 3-H H-15 J = 6 Hz), 1.30 (m, 22-H, H-2,3,4,7,8,9,10,11,12,13 & 14) 2.22 (m, 2-H, H-5 & 6).

**¹³C-NMR (DMSO, δppm):** 28.11 (CH₃ C-5), 30.32 (CH₃ C-14), 30.53 (C-13), 30.58 (C-12), 30.65 (C-11), 30.73 (C-10), 30.75 (C-9) 30.82 (C-8), 33.05 (C-7), 130.6 (C-5,6), 48.57 (C-4), 49.14 (C-3), 49.43 (C-2), 180.69 (C-1). The chemical structure of compound IV (Figure 4) was further elucidated through HMBC, HSQC and COSY spectral techniques.

![Figure 4: Compound IV (5-Pentadecanoic acid)](image)

**DPPH and ABTS scavenging potential**

To find out whether the isolated compounds would be useful in scavenging free radical produced inside human bodies or not, their antioxidant potential was evaluated using the DPPH and ABTS assays. In DPPH assay, the DPPH free radical developed react with the test substance and after quenching the free radical the change in absorbance at 515 nm is noted. The 5-pentadecanoic acid showed maximum scavenging potentials with IC₅₀ = 64 μg/mL (85.33 ± 2.60 % at 1000 μg/mL) followed by stigmasterol (IC₅₀ = 65 μg/mL, and % inhibition = 84.01 ± 1.79). Compound II and III also exhibited excellent DPPH scavenging with percent inhibition of 82.19 ± 2.33 and 81.68 ± 1.90 μg/mL (IC₂₀ = 90 and 93 μg/mL respectively) as shown in Table 1.

The ABTS free radical was also more potently inhibited by 5-pentadecanoic acid, which showed highest percent inhibition of 84.43 ± 1.71 at 1000 μg/mL concentration with IC₅₀ value 65 μg/mL followed by stigmasterol (IC₅₀ = 66 μg/mL and % inhibition = 83.23 ± 2.55). Compound II and III also exhibited notable ABTS scavenging potential with IC₅₀ of 86 and 98 μg/mL respectively (Table 1). Ascorbic acid (IC₅₀ = 35 μg/mL) was used as positive control.

**Cholinesterase inhibition**

In a number of neurological disorders, the inhibition of AChE and BChE are desired to inhibit the hydrolysis of acetylcholine. Table 2 representing the anticholinesterases inhibitory potential of the isolated compounds isolated. Against AChE, stigmasterol was more potent and showed a percent inhibition of 85.10 ± 1.45 with IC₅₀ of 63 μg/mL, followed by betulinic acid with percent inhibition of 83.26 ± 1.69 (IC₅₀ = 69 μg/mL). The compound III and IV also inhibited the mentioned enzyme with the IC₅₀ of 72 and 73μg/mL respectively (Table 2) and were ranked as moderate inhibitors of AChE.

Galantamine was used as positive control. The isolated compounds also exhibited substantial inhibition of BChE. The stigmasterol showed remarkable inhibition with percent inhibition of 84.81 ±1.17% (IC₂₀ = 67 μg/mL) followed by 5-pentadecanoic acid (IC₅₀ = 69 μg/mL). Betulinic acid and 1,2,3-benzene triol were also found to have high percent inhibition with IC₅₀ of 71 and 82 μg/mL, respectively (Table 2).
Table 1: Free radical scavenging activities of compounds I to IV

| Compound     | Conc (µg/mL) | DPPH inhibition (%, mean ± SEM) | IC₅₀ (µg/mL) | ABTS inhibition (%), mean ± SEM | IC₅₀ (µg/mL) |
|--------------|-------------|-------------------------------|-------------|---------------------------------|-------------|
| Stigmasterol | 1000        | 84.01 ± 1.79***               | 83.23 ± 2.55*** |                                  |             |
|              | 500         | 73.14 ± 1.65***               | 73.65 ± 2.75*** |                                  |             |
|              | 125         | 54.72 ± 2.54***               | 64.20 ± 1.84*** |                                  |             |
|              | 62.5        | 46.11 ± 1.87**                | 56.13 ± 1.34*** |                                  |             |
|              | 1000        | 82.19 ± 2.33***               | 47.64 ± 1.20*** |                                  |             |
|              | 500         | 76.24 ± 2.65***               | 81.28 ± 2.15*** |                                  |             |
| Betulinic acid | 250       | 61.47 ± 2.73***               | 75.19 ± 2.65*** |                                  |             |
|              | 125         | 53.66 ± 1.19***               |             |                                  |             |
|              | 62.5        | 43.49 ± 2.72**                |             |                                  |             |
|              | 1000        | 81.68 ± 1.90***               |             |                                  |             |
|              | 500         | 71.44 ± 1.61***               |             |                                  |             |
|              | 250         | 64.80 ± 1.65***               |             |                                  |             |
|              | 125         | 54.63 ± 1.87***               |             |                                  |             |
| 1,2,3 benzene triol | 1000 | 81.22 ± 2.89***               |             |                                  |             |
|              | 500         | 73.41 ± 2.87***               |             |                                  |             |
|              | 250         | 64.15 ± 2.88***               |             |                                  |             |
|              | 125         | 54.86 ± 2.86***               |             |                                  |             |
| 5-Pentadecanoic acid | 250   | 65.21 ± 0.96***               |             |                                  |             |
|              | 125         | 55.89 ± 2.98***               |             |                                  |             |
|              | 62.5        | 47.66 ± 2.78***               |             |                                  |             |
| Ascorbic acid | 250        | 78.63±1.48                    |             |                                  |             |
|              | 125         | 65.35±1.08                    |             |                                  |             |
|              | 62.5        | 55.12±1.30                    |             |                                  |             |

Table 2: Anticholinesterase activity of compounds I-IV

| Compound     | Conc. (µg/mL) | % AChE Inhibition (mean ± SEM) | IC₅₀ (µg/mL) | % BChE inhibition (mean ± SEM) | IC₅₀ (µg/mL) |
|--------------|---------------|-------------------------------|-------------|-------------------------------|-------------|
| Stigmasterol | 1000          | 85.10 ± 1.45***               | 84.81 ± 1.17*** |                                  |             |
|              | 500           | 75.63 ± 2.60***               | 72.20 ± 1.90*** |                                  |             |
|              | 125           | 54.32 ± 1.89***               | 54.45 ± 0.96*** |                                  |             |
|              | 62.5          | 48.57 ± 2.03*                 | 47.65 ± 1.74*** |                                  |             |
|              | 1000          | 81.26 ± 1.68***               | 82.67 ± 1.87*** |                                  |             |
|              | 500           | 75.63±2.78***                 | 73.43 ± 2.08*** |                                  |             |
| Betulinic acid | 250         | 63.80 ± 1.50                  | 63.32 ± 1.60*** |                                  |             |
|              | 125           | 54.76 ± 0.97***               | 54.36 ± 2.73*** |                                  |             |
|              | 62.5          | 45.52 ± 2.67***               | 46.45 ± 2.62*** |                                  |             |
|              | 1000          | 81.22±2.89***                 | 79.87 ± 2.65*** |                                  |             |
|              | 500           | 74.28±2.43***                 | 70.37 ± 2.37*** |                                  |             |
| 1,2,3 benzene triol | 250   | 64.15 ± 2.10***               | 60.39 ± 1.71*** |                                  |             |
|              | 125           | 54.86 ± 2.86***               | 51.10 ± 1.39*** |                                  |             |
| 5-Pentadecanoic acid | 250   | 65.60 ± 1.82***               | 64.33 ± 2.20*** |                                  |             |
|              | 125           | 53.25 ± 1.54***               | 54.17 ± 3.11*** |                                  |             |
|              | 62.5          | 48.89 ± 2.61***               | 45.69 ± 2.20*** |                                  |             |
| Galantamine  | 250           | 77.13±1.08                    | 76.74 ± 2.26*** |                                  |             |
|              | 125           | 64.15±2.70                    | 64.89 ± 1.85  |                                  |             |
|              | 62.5          | 53.02±2.31                    | 53.71 ± 1.69  |                                  |             |

Sim provide a scientific base for the observed in vitro anticholinesterase potentials of isolated compounds, molecular docking software was used to determine the most favorable binding between the enzyme active sites and the isolated compounds. The most potent inhibitor of AChE i.e compound I exhibited a docking score of - 8.622 Kcal/mol showing the excellent fitting of
the compound in the binding pocket of enzyme protein crystal structure (Figure 1). The favorable interaction of ligand with Tyr-70, Trp-84 and His-440 is shown in Figure 1a and b. On the other hand, benzene triol exhibited excellent overlapping and fitness in the binding pockets of both cholinesterases with a docking score of -7.008 (AChE) and -2.746 Kcal/mol (BChE). The OH group of the said ligand form H-B (1.89 Å) linkage with HOH-622. There is also some pi stacking interaction with PHE-330 of AChE and the ligand as presented in Figure 2a, and b. The BChE has also exhibited good interaction with 1, 2, 3 benzene triol, OH of the ligand form H-B (1.86 Å) linkage with carbonyl of ASP-332. OH group of the same ligand also forms H-B (1.94 Å) linkage with NH2 of GLN-333 as presented in Figure 2c, and d.

**DISCUSSION**

Based on the ethno pharmacological uses of *Z. oxyphylla* [5], an attempt was made to isolate phytochemicals from this plant. To the best of our knowledge, the roots of *Ziziphus oxyphylla* have not been evaluated or subjected to the isolation of phytochemicals before. The lack of information about the chemical composition of this plant and diverse medicinal uses of genus *Ziziphus*, *Ziziphus oxyphylla* roots in folklore medicines promoted to investigate its phytochemical constituents. The investigations led to the isolation four compounds which were confirmed through different spectroscopic techniques. First, the plant was subjected to the extraction and fractionation.

During metabolism a number of free radicals are formed. Normally, they are detoxified by body defense mechanisms as soon as they are formed. However, their overproduction can lead to a number of health complications including heart diseases, neurodegenerative disorders, suppression of immune system, and metabolic disorders [9]. A number of chemical substances called antioxidants, help in quenching the free radical produced thus maintaining the homeostasis of the body [22]. The isolated compounds showed substantial free radical scavenging activities against the studied synthetic free radicals; DPPH and ABTS. The lowest IC50 value of 64 μg/mL (85.33 ± 2.60 percent inhibition at 1000 μg/mL) was recorded for 5-pentadecanoic acid while against ABTS radical its IC50 value was 65 μg/mL. Substantial DPPH scavenging was also observed for compound II and III with percent inhibition of 82.19 ± 2.33 and 81.68 ± 1.90 (IC50 = 90 & 93 μg/mL) respectively.

The fractions were subjected HPLC analysis and the chromatograms obtained were compared for the phytochemicals present. The ethyl acetate extract was found to contain more phytochemicals and was thus used in the subsequent isolation process. Betulinic acid, stigmasterol, 1,2,3-benzene triol and 5-pentadecanoic were isolated in pure form from this fraction. Amongst the isolated compounds, the stigmasterol has been reported previously from this genus while the other three are hereby reported for the first time from the selected plant.

**Figure 1:** Molecular docking photograph of the high ranked pose of the AChE active site and compound I (green). (a) 2D diagram of ligand (AChE) protein and residue contact. (b) Docked ligand and active binding pocket of AChE

**Figure 2:** Molecular docking photograph of the high ranked pose of selected cholinesterases active sites and compound III (green) showing that it has been bound with the active site close to H2O molecule. (a). 2D diagram of ligand (AChE) protein and residue contact: (b). Docked ligand and active binding pocket of AChE; (c). 2D diagram of ligand (BChE) protein and residue contact: (d). Docked ligand and active binding pocket of BChE
associated with Alzheimer's and other neurologic diseases [22,23]. The isolated compounds showed remarkable AChE and BChE inhibitory activities as well. The AChE was more potently inhibited by stigmasterol with percent inhibition of 85.10±1.45% and IC\textsubscript{50} of 63 μg/mL, followed by betulinic acid with percent inhibition of 83.26±1.69 (IC\textsubscript{50} = 69 μg/mL). The compound \textbf{III} and \textbf{IV} with the IC\textsubscript{50} values of 72 and 69 respectively, were ranked as moderate inhibitors of the AChE.

The isolated compounds exhibited substantial activities against the BChE. Amongst them stigmasterol showed maximum anticholinesterase activity of 84.81 ±1.17% with an IC\textsubscript{50} value of 67 μg/mL followed by 5-pentadecanoic acid (IC\textsubscript{50} = 69 μg/mL). Compound \textbf{II} and \textbf{III} were also found to have strong anticholinesterase potentials which is evident from their IC\textsubscript{50} values (71 and 82 μg/mL respectively). Galantamine, a compound from plant origin was used as positive control.

**CONCLUSION**

Almost all the compounds (I-IV) exhibit scavenging activities against ABTS and DPPH radicals, and potentially inhibited cholinesterases. Stigmasterol and 5-pentadecanoic acid displayed the highest activities. \textit{Ziziphus oxyphylla} is already in use as a folklore remedy in a number of health complications but further investigations are needed to isolate new biologically active secondary metabolites, which might have beneficial effects on various health disorders in human.

**DECLARATIONS**

**Acknowledgement**

This research work was financially supported by HEC, Pakistan under NRPU Projects program no. 20-2515.

**Conflicts of interest**

No conflict of interest is associated with this work.

**Availability of the data and materials**

The findings reported in this study are part of Irfan Khan’s PhD thesis and will be deposited in HEC Pakistan repository on completion of the project and thus would be available online.

**Author contributions**

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors. I.K. & M.Z. designed the study; all the authors equally contributed in performing the experiments and write up of the paper (I.K, A.Z, W.B, M.U.K.S, S.N. & M.Z).

**Open Access**

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/ra-d), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

**REFERENCES**

1. Gopukumar S, Alexander P, Jainamboo M, Praseetha P. Phytochemical screening and FT-IR analysis of \textit{Ficus benghalensis} fruits. Int J Pharmacog Phytochem Res 2016; 8: 1529-1534.
2. Tiwari P, Kumar B, Kaur M, Kaur G, Kaur H. Phytochemical screening and extraction: a review. Int Pharma Sci 2011; 1: 98-106.
3. Paul A, Vibhuti A, Raj S. Preliminary phytochemical screening of \textit{Camellia sinensis} & \textit{Tinospora cordifolia} used in traditional medicine. Int J Pharm Bio Sci 2016; 7: 187-193.
4. Hussain J, Ali L, Khan A, Rehman N, Jabeen F, Kim J-S, Al-Harrasi A. Isolation and bioactivities of the flavonoids \textit{morin} and \textit{mori}-3-O-β-D-glucopyranoside from \textit{Acridocarpus orientalis}—A wild Arabian medicinal plant. Molecules 2014; 19: 17763-17772.
5. Banu KS, Cathrine L. General techniques involved in phytochemical analysis. Int J Adv Res Chem Sci 2015; 2: 25-32.
6. Santhi K, Sengottuvel R. Qualitative and quantitative phytochemical analysis of \textit{Moringa concanensis} Nimmo. Int J Curr Microbio App Sci 2016; 5: 633-640.
7. Ochwang'I D, Kimwele C, Oduma J, Gathumbi P, Kiama S. Phytochemical screening of medicinal plants of the Kakamega Country, Kenya commonly used against Cancer. Medicinal and Aromatic Plants (Los Angel) 2016; 5: 2167-0412.
8. Russo D, Valentão P, Andrade P, Fernandez E, Milella L. Evaluation of antioxidant, antidiabetic and anticholinesterase activities of \textit{Smallanthus sonchifolius} landraces and correlation with their phytochemical profiles. Int J Mol Sci 2015; 16: 17696-17718.
9. Ovais M, Ayaz M, Khalil AT, Shah SA, Jan MS, Raza A, Shahid M, Shinwari ZK. HPLC-DAD finger printing, antioxidant, cholinesterase, and α-glucosidase inhibitory potentials of a novel plant Olax nana. BMC Compl Alt Med 2018; 18: 1.

10. Dastjerdi ZM, Namjooan F, Azemi ME. Alpha amylase inhibition activity of some plants extract of Teucrium species. Eur J Bio Sci 2015; 7: 26-31.

11. Nisar M, Kaleem WA, Qayum M, Marwat IK, Zia-Ul-Haq M, Ali I, Choudhary M. Biological screening of Zizyphus oxyphylla Edgew stem. Pak J Bot 2011; 43: 311-317.

12. Ahmad R, Upadhyay A, Ahmad M, Pieters L. Antioxidant, antilglycation and antimicrobial activities of Zizyphus oxyphylla and Cedrela serrata Extracts. Eur J Med Plant 2013; 3: 520-529.

13. Kaleem WA, Nisar M, Qayum M, Zia-Ul-Haq M, Choudhary MI, ERCIŞLİ S. Urease inhibitory potential of Zizyphus oxyphylla Edgew. extracts and isolated compounds. Turk J Med Sci 2013; 43: 497-500.

14. Lakache Z, Tigrine-Kordjani N, Tigrine C, Aliboudhar H, Kameil A. Phytochemical screening and antioxidant properties of methanolic extract and different fractions of Crataegus azarolus leaves and flowers from Algeria. Int Food Res J 2016; 23.

15. Devi S, Pandey V, Singh J, Shah A. Peptide alkaloids from Zizyphus species. Phytochemistry 1987; 26: 3374-3375.

16. Singh B, Pandey V. An N-formyl cyclopeptide alkaloid from Zizyphus nummularia bark. Phytochemistry 1995; 38: 271-273.

17. Ghedira K, Chemli R, Caron C, Nuzillard J-M, Zeches M, Le Men-Olivier L. Four cyclopeptide alkaloids from Zizyphus lotus. Phytochemistry 1995; 38: 767-772.

18. Tripathi M, Pandey M, Jha R, Pandey V, Tripathi P, Singh J. Cyclopeptide alkaloids from Zizyphus jujuba. Fitoterapia 2001; 72: 507-510.

19. Le Crouéour G, Thépenier P, Richard B, Petermann C, Ghédira K, Zeches-Hanrot M. Lotusine G: a new cyclopeptide alkaloid from Zizyphus lotus. Fitoterapia 2002; 73: 63-68.

20. Ayaz M, Junaid M, Ahmed J, Ullah F, Sadiq A, Ahmad S, Imran M. Phenolic contents, antioxidant and anticholinesterase potentials of crude extract, subsequent fractions and crude saponins from Polygonum hydropiper L. BMC Compl Alt Med 2014; 14: 145.

21. Pintus F, Matos MJ, Vilar S, Hrippsak G, Varela C, Uriarte E, Santana L, Borges F, Medda R, Di Petrillo A. New insights into highly potent tyrosinase inhibitors based on 3-heteroarylcoumarins: Anti-melanogenesis and antioxidant activities, and computational molecular modeling studies. Bioorg Med Chem 2017; 25: 1687-1695.

22. Nawaz SA, Choudhary MI. New cholinesterase inhibiting bisbenzylisoquinoline alkaloids from Cocculus pendulus. Chem Pharm Bull 2004; 52: 802-806.

23. Xiao S, Wang T, Ma X, Qin Y, Li X, Zhao Z, Liu X, Wang X, Xie H, Jiang Q. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a phase II multicenter randomised controlled trial. Age Ageing 2017; 46: 767-773.

24. Jacob RA. The integrated antioxidant system. Nutr Res 1995; 15: 755-766.